经肝动脉输液泵化疗在结直肠癌肝转移治疗中的临床应用进展

doi:10.3969/j.issn.1672-5069.2024.03.039

摘要/Abstract

摘要： 肝脏是结直肠癌血行转移最主要的靶器官,约有50%结直肠癌最终会发生肝转移,肝转移已经成为影响结直肠癌患者预后的重要不利因素。肝动脉是结直肠癌肝转移瘤的主要供血动脉,经肝动脉灌注化疗药物可提高肿瘤局部药物浓度和化疗效果,植入式输液泵可更简便地为患者提供长期灌注化疗。经肝动脉输液泵灌注化疗在术前转化降期治疗和术后辅助治疗方面展现出显著的疗效,可有效提高结直肠癌肝转移肿瘤手术切除的可行性和降低术后复发率。经肝动脉输液泵氟脲苷化疗可作为结直肠癌肝转移的二、三线治疗方案,联合全身化疗和靶向治疗等可为患者带来较好的生存获益。本文综述了经肝动脉输液泵化疗治疗结直肠癌肝转移临床应用及研究进展。

关键词: 肝转移癌, 结直肠癌, 肝动脉输液泵灌注化疗, 氟脲苷

Abstract: The liver is the most common organ of hematogenous metastasis of colorectal cancer, and about 50% of colorectal cancers will eventually develop liver metastasis, which have become an important untoward factor affecting the survival and prognosis of patients with colorectal cancer. The hepatic artery is the main blood supply vessel for colorectal liver metastases (CRLM), and direct infusion of chemotherapeutic agents through the hepatic artery can improve the local drug concentration and anti-tumor effects. The implantable infusion pumps provide convenient tunnels for infusion chemotherapy easily. The hepatic arterial infusion pump (HAIP) chemotherapy has shown a promising effect in preoperative transformation or downstage of tumors and postoperative adjuvant therapy, which can effectively improve the feasibility of surgical resection of CRLM and reduce the postoperative recurrence rate. The fluorouridine chemotherapy by HAIP can be applied as second or third lines of treatment for patients with CRLM. The HAIP and systemic chemotherapy combination plus targeted therapy can bring better survival benefits for patients in this setting. This article will review and discuss the clinical applications and advances of HAIP chemotherapy in the surgical treatment of CRLM.

Key words: Liver metastases, Colorectal cancer, Hepatic artery infusion pump, Infusion chemotherapy, Fluorouridine

马瑞东, 罗诗樵. 经肝动脉输液泵化疗在结直肠癌肝转移治疗中的临床应用进展[J]. 实用肝脏病杂志, 2024, 27(3): 473-476.

Ma Ruidong, Luo Shiqiao. Hepatic arterial infusion pump chemotherapy in treatment of patients with colorectal liver metastases[J]. Journal of Practical Hepatology, 2024, 27(3): 473-476.

参考文献

[1] Adam R, Vinet E. Regional treatment of metastasis: surgery of colorectal liver metastases. Ann Oncol, 2004,15 (Suppl 4):v103-v106.
[2] Giannis D, Sideris G, Kakos C D, et al. The role of liver transplantation for colorectal liver metastases: a systematic review and pooled analysis. Transplant Rev (Orlando), 2020,34(4):100570.
[3] Qin S, Liu G J, Huang M, et al. The local efficacy and influencing factors of ultrasound-guided percutaneous microwave ablation in colorectal liver metastases: a review of a 4-year experience at a single center. Int J Hyperthermia, 2019,36(1):36-43.
[4] Archer S G, Gray B N. Vascularization of small liver metastases. Br J Surg, 1989,76(6):545-548.
[5] Buisman F E, Homs M, Grunhagen D J, et al. Adjuvant hepatic arterial infusion pump chemotherapy and resection versus resection alone in patients with low-risk resectable colorectal liver metastases - the multicenter randomized controlled pump trial. BMC Cancer, 2019,19(1):327.
[6] Power D G, Kemeny N E. The role of floxuridine in metastatic liver disease. Mol Cancer Ther, 2009,8(5):1015-1025.
[7] Buisman F E, Grunhagen D J, Homs M, et al. Adjuvant hepatic arterial infusion pump chemotherapy after resection of colorectal liver metastases: results of a safety and feasibility study in the Netherlands. Ann Surg Oncol, 2019,26(13):4599-4607.
[8] Creasy J M, Napier K J, Reed S A, et al. Implementation of a hepatic artery infusion program: initial patient selection and perioperative outcomes of concurrent hepatic artery infusion and systemic chemotherapy for colorectal liver metastases. Ann Surg Oncol, 2020,27(13):5086-5095.
[9] Dizon D S, Schwartz J, Kemeny N. Regional chemotherapy: a focus on hepatic artery infusion for colorectal cancer liver metastases. Surg Oncol Clin N Am, 2008,17(4):759-771.
[10] IJzerman N S, Filipe W F, Bruijn P, et al. Systemic exposure of floxuridine after hepatic arterial infusion pump chemotherapy with floxuridine in patients with resected colorectal liver metastases. Biomed Pharmacother, 2023,162:114625.
[11] Datta J, Narayan R R, Kemeny N E, et al. Role of hepatic artery infusion chemotherapy in treatment of initially unresectable colorectal liver metastases: a review. JAMA Surg, 2019,154(8):768-776.
[12] Li Y. Analysis of hepatic artery infusion (HAI) chemotherapy using randomized trials of floxuridine (FUDR) for colon cancer patients with multiple liver metastases. Gastroenterol Res Pract, 2022,2022:3546455.
[13] Ranieri G, Laforgia M, Nardulli P, et al. Oxaliplatin-based intra-arterial chemotherapy in colo-rectal cancer liver metastases: a review from pharmacology to clinical application. Cancers (Basel), 2019,11(2):1138-1142.
[14] Allen-Mersh T G, Glover C, Fordy C, et al. Randomized trial of regional plus systemic fluorinated pyrimidine compared with systemic fluorinated pyrimidine in treatment of colorectal liver metastases. Eur J Surg Oncol, 2000,26(5):468-473.
[15] Kemeny N E, Niedzwiecki D, Hollis D R, et al. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). J Clin Oncol, 2006,24(9):1395-1403.
[16] Chen Y, Wang X, Yan Z, et al. Hepatic arterial infusion with irinotecan, oxaliplatin, and floxuridine plus systemic chemotherapy as first-line treatment of unresectable liver metastases from colorectal cancer. Onkologie, 2012,35(9):480-484.
[17] Li C, Gu Y, Zhao M, et al. Phase I trial of hepatic arterial infusion (HAI) of floxuridine with modified oxaliplatin, 5-fluorouracil and leucovorin (m-FOLFOX6) in Chinese patients with unresectable liver metastases from colorectal cancer. Cancer Chemother Pharmacol, 2014,74(5):1079-1087.
[18] Bentrem D J, Dematteo R P, Blumgart L H. Surgical therapy for metastatic disease to the liver. Annu Rev Med, 2005,56:139-156.
[19] Kemeny N E, Melendez F D, Capanu M, et al. Conversion to resectability using hepatic artery infusion plus systemic chemotherapy for the treatment of unresectable liver metastases from colorectal carcinoma. J Clin Oncol, 2009,27(21):3465-3471.
[20] Ammori J B, Kemeny N E, Fong Y, et al. Conversion to complete resection and/or ablation using hepatic artery infusional chemotherapy in patients with unresectable liver metastases from colorectal cancer: a decade of experience at a single institution. Ann Surg Oncol, 2013,20(9):2901-2907.
[21] Pak L M, Kemeny N E, Capanu M, et al. Prospective phase II trial of combination hepatic artery infusion and systemic chemotherapy for unresectable colorectal liver metastases: long term results and curative potential. J Surg Oncol, 2018,117(4):634-643.
[22] Kolbeinsson H M, Preihs R, Bengel A, et al. Kirsten rat sarcoma (KRAS) oncogene mutation predicts magnitude of response and outcomes in hepatic arterial infusion pump therapy of unresectable colorectal liver metastases. J Gastrointest Oncol, 2022,13(1):163-170.
[23] Boileve A, De Cuyper A, Larive A, et al. Hepatic arterial infusion of oxaliplatin plus systemic chemotherapy and targeted therapy for unresectable colorectal liver metastases. Eur J Cancer, 2020,138:89-98.
[24] Cercek A, Boucher T M, Gluskin J S, et al. Response rates of hepatic arterial infusion pump therapy in patients with metastatic colorectal cancer liver metastases refractory to all standard chemotherapies. J Surg Oncol, 2016,114(6):655-663.
[25] O'Leary M P, Wang C, Sandhu J, et al. Salvage regional therapy using hepatic artery infusion pump in unresectable chemotherapy resistant colorectal liver metastases. Am J Surg, 2022,223(6):1151-1156.
[26] Tomlinson J S, Jarnagin W R, DeMatteo R P, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol, 2007,25(29):4575-4580.
[27] Kemeny M M, Adak S, Gray B, et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy--an intergroup study. J Clin Oncol, 2002,20(6):1499-1505.
[28] Kemeny N, Capanu M, D'Angelica M, et al. Phase I trial of adjuvant hepatic arterial infusion (HAI) with floxuridine (FUDR) and dexamethasone plus systemic oxaliplatin, 5-fluorouracil and leucovorin in patients with resected liver metastases from colorectal cancer. Ann Oncol, 2009,20(7):1236-1241.
[29] Sadot E, Groot K B, Leal J N, et al. Resection margin and survival in 2368 patients undergoing hepatic resection for metastatic colorectal cancer: surgical technique or biologic surrogate? Ann Surg, 2015,262(3):476-485.
[30] Srouji R, Narayan R, Boerner T, et al. Addition of adjuvant hepatic artery infusion to systemic chemotherapy following resection of colorectal liver metastases is associated with reduced liver-related mortality. J Surg Oncol, 2020,121(8):1314-1319.
[31] Gholami S, Kemeny N E, Boucher T M, et al. Adjuvant hepatic artery infusion chemotherapy is associated with improved survival regardless of KRAS mutation status in patients with resected colorectal liver metastases: a retrospective analysis of 674 patients. Ann Surg, 2020,272(2):352-356.
[32] Kemeny N E, Jarnagin W R, Capanu M, et al. Randomized phase II trial of adjuvant hepatic arterial infusion and systemic chemotherapy with or without bevacizumab in patients with resected hepatic metastases from colorectal cancer. J Clin Oncol, 2011,29(7):884-889.
[33] Kemeny N E, Chou J F, Capanu M, et al. A randomized phase II trial of adjuvant hepatic arterial infusion and systemic therapy with or without panitumumab after hepatic resection of KRAS wild-type colorectal cancer. Ann Surg, 2021,274(2):248-254.
[34] Buisman F E, Filipe W F, Kemeny N E, et al. Recurrence after liver resection of colorectal liver metastases: repeat resection or ablation followed by hepatic arterial infusion pump chemotherapy. Ann Surg Oncol, 2021,28(2):808-816.